Enrollment is underway for the first chronic pain study to quantify real-life outcomes and develop digital biomarkers in 10,000 individuals
San Mateo, CA– February 12, 2018 – Today, Evidation Health announces the launch of Digital Signals in Chronic Pain (the DiSCover Project) – a 10,000 person chronic pain study to quantify real-life outcomes in chronic pain patients and develop digital biomarkers for chronic pain severity, pain flare ups, and quality of life. This is the first large-scale study in the U.S. to digitally obtain and analyze everyday behavioral data to more completely understand outcomes in individuals experiencing chronic pain.
Chronic pain affects more Americans than diabetes, heart disease and cancer combined, with an estimated 100 million Americans experiencing chronic pain conditions. Despite the high prevalence of chronic pain, finding effective treatment options is significantly complicated by the fact that each person experiences chronic pain in a different way day to day. This study aims to shed new light on the spectrum of chronic pain experiences in individuals through new digital methods.
The DiSCover Project leverages Evidation’s technology platform to run virtual studies with novel real-life data sources — including data from connected devices, weather, and diet — alongside more traditional medical information, such as patient reported outcomes, genomic information, and clinical lab data. The platform uses machine learning to identify the digital signals tied to health outcomes, such as pain severity and flare up events.
“The widespread use of wearables, sensors and digital health tools gives us an opportunity to quantify the real lives of patients who suffer from chronic pain — now a critically important public health condition in the U.S.,” said Deborah Kilpatrick, Ph.D., CEO of Evidation Health. “We are running this large-scale pain study to gain powerful insights on how behavioral factors are associated with health outcomes of chronic pain patients.”
“Novel research methodologies will enable the quantification of real-life outcomes in chronic pain across thousands of patients. ” said Christine Sang, M.D., MPH, director of Translational Pain Research at Brigham and Women’s Hospital and a consultant to the study. “If successful, the real-life insights on individual patient-level experiences can inform our efforts to bring relief to the striking number of people with diverse experiences of chronic pain.”
About Evidation Health
Evidation Health is a technology and services company that helps individuals and the world’s most innovative healthcare companies understand and influence the everyday behaviors that create better health outcomes. Evidation pairs a first of its kind discovery engine designed for better, faster, and more efficient studies with a delivery platform that connects individuals and the healthcare industry. The company is headquartered in San Mateo, CA, with additional offices in Santa Barbara, CA. For more information, please visit evidation.com.